In 2017, Pandora billionaire René Sindlev took matters into his own hands. He had been a key shareholder of the cancer biotech Dandrit for years, but apparently he had had enough: He took the reins and put Dandrit to rest. The company had been working on a failed cancer vaccine, MCV, which according to Sindlev "couldn't even be given away".
Enochian Biosciences has a market cap of $238 million, but researchers doubt the company: "There is no scientific documentation to base their claim on"
Enochian Biosciences emerged from the ashes of Dandrit and is currently valued at $238 million because of a preclinical, potential cure for HIV and a researcher that management has frequently named a "genius". But scientists doubt the company.
BY PETER THOMSEN AND KEVIN GRØNNEMANN
Already a subscriber?Log in here
Buy a subscription and get access to all of MedWatch
Personal subscription
With a personal subscription you get:
- Premium access to all content on MedWatch
- Unlimited access to our archive
- Daily newsletters with the most important industry news
- Top newsletters when the biggest industry news breaks
- Login to our app - industry news on the go
Corporate subscription
With a corporate subscription you get:
- All the benefits of a personal subscription
- Solution tailored to your company's needs
- Attractive price per user
Try MedWatch for 14 days - and get access to all content.
Get a non-binding trial subscription here.You need to be a subscriber to read the rest of the article.
